Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder
- PMID:12191627
- DOI: 10.1016/s0022-3956(02)00010-9
Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder
Abstract
The early identification of likely remitters and non-remitters to pharmacotherapy for panic disorder may have important implications for clinical treatment decisions. To address this question, combined data from two fixed-dose and two flexible dose placebo-controlled studies of sertraline treatment of panic disorder were examined. Patients (N=544) diagnosed with panic disorder, with or without agoraphobia, were treated with 50 mg of sertraline, 100 mg of sertraline, flexible dosages of sertraline, or placebo. Measures of early improvement included panic attack frequency (full + limited symptom attacks), anticipatory anxiety, the Hamilton Anxiety Rating Scale (HAM-A), and the Clinical Global Impression Improvement (CGI-I) Scale. Improvement as reflected in CGI-I ratings and change from baseline in the HAM-A at weeks 1, 2, and 3 significantly (P<0.0001) predicted endpoint clinical remission (defined at endpoint as no full panic attacks and a CGI-Severity rating of 1 or 2). Improvements in panic attack frequency and anticipatory anxiety were not consistent predictors in multivariate predictive models. Receiver-Operator Curve analyses revealed good specificity (0.83) for change in CGI-I at week 2, and good sensitivity (0.82) for change in HAM-A at week 3. Predictive success for HAM-A and CGI-I was not significantly different for fixed vs. flexible dose sertraline treatment, nor for sertraline vs. placebo treatment. The use of ROC analyses for examination of early response as a predictor of final remission holds promise for aiding clinicians in decision making regarding the need for alternative or supplemental treatment approaches during the course of pharmacotherapy for panic disorder.
Copyright 2002 Elsevier Science Ltd.
Similar articles
- Sertraline treatment of panic disorder: response in patients at risk for poor outcome.Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R.Pollack MH, et al.J Clin Psychiatry. 2000 Dec;61(12):922-7.J Clin Psychiatry. 2000.PMID:11206597
- Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R.Pollack MH, et al.Arch Gen Psychiatry. 1998 Nov;55(11):1010-6. doi: 10.1001/archpsyc.55.11.1010.Arch Gen Psychiatry. 1998.PMID:9819070Clinical Trial.
- Sertraline in the treatment of panic disorder: a double-blind multicenter trial.Pohl RB, Wolkow RM, Clary CM.Pohl RB, et al.Am J Psychiatry. 1998 Sep;155(9):1189-95. doi: 10.1176/ajp.155.9.1189.Am J Psychiatry. 1998.PMID:9734541Clinical Trial.
- Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.Bakker A, van Balkom AJ, van Dyck R.Bakker A, et al.Int Clin Psychopharmacol. 2000 Aug;15 Suppl 2:S25-30. doi: 10.1097/00004850-200008002-00005.Int Clin Psychopharmacol. 2000.PMID:11110016Review.
- [Efficacy and tolerability of escitalopram in anxiety disorders: a review].Pelissolo A.Pelissolo A.Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15.Encephale. 2008.PMID:18922243Review.French.
Cited by
- Predictors of pharmacotherapy response in anxiety disorders.Denys D, de Geus F.Denys D, et al.Curr Psychiatry Rep. 2005 Aug;7(4):252-7. doi: 10.1007/s11920-005-0078-4.Curr Psychiatry Rep. 2005.PMID:16098278Review.
- Identifying HAM-A cutoffs for mild, moderate, and severe generalized anxiety disorder.Matza LS, Morlock R, Sexton C, Malley K, Feltner D.Matza LS, et al.Int J Methods Psychiatr Res. 2010 Dec;19(4):223-32. doi: 10.1002/mpr.323. Epub 2010 Aug 18.Int J Methods Psychiatr Res. 2010.PMID:20718076Free PMC article.
- Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study.Oh KS, Shin E, Ha J, Shin D, Shin Y, Lim SW.Oh KS, et al.Clin Psychopharmacol Neurosci. 2016 May 31;14(2):161-7. doi: 10.9758/cpn.2016.14.2.161.Clin Psychopharmacol Neurosci. 2016.PMID:27121427Free PMC article.
- Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial.Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, Moshier SJ, Zalta AK, Pollack MH.Simon NM, et al.J Clin Psychiatry. 2009 Nov;70(11):1563-70. doi: 10.4088/JCP.08m04485blu. Epub 2009 Oct 6.J Clin Psychiatry. 2009.PMID:19814948Free PMC article.Clinical Trial.
- Benzodiazepines versus placebo for panic disorder in adults.Breilmann J, Girlanda F, Guaiana G, Barbui C, Cipriani A, Castellazzi M, Bighelli I, Davies SJ, Furukawa TA, Koesters M.Breilmann J, et al.Cochrane Database Syst Rev. 2019 Mar 28;3(3):CD010677. doi: 10.1002/14651858.CD010677.pub2.Cochrane Database Syst Rev. 2019.PMID:30921478Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical